Storia in 9 fonti

AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic

AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.com1 g fa

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie acquires Apogee for $10.9B to add zumilokibart, an immunology drug dosed 2–4 times yearly for inflammatory diseases. The deal signals pharma's trend toward consolidation via focused biotech acquisitions—key signal for partnership and M&A strategy.

Leggi questa versione → originale

Timeline cronologica

lunedì 22 giugno 2026·biopharmadive.com
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster”…
lunedì 22 giugno 2026·endpoints.news
AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates
AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.

AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic

Confronto fonti

AbbVie to buy Apogee Therapeutics in nearly $11B deal

Timeline cronologica

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie Goes On The Offensive With $10.9 Billion Takeover

AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News

AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie acerta aquisição da Apogee Therapeutics por US$ 10,9 bilhões em dinheiro

Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther

AbbVie Goes On The Offensive With $10.9 Billion Takeover

AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monda

AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News

AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic